$232.23 Million in Sales Expected for Prestige Consumer Healthcare Inc (NYSE:PBH) This Quarter

Brokerages expect that Prestige Consumer Healthcare Inc (NYSE:PBH) will report sales of $232.23 million for the current quarter, according to Zacks. Four analysts have provided estimates for Prestige Consumer Healthcare’s earnings, with the lowest sales estimate coming in at $230.80 million and the highest estimate coming in at $234.70 million. Prestige Consumer Healthcare posted sales of $253.98 million in the same quarter last year, which suggests a negative year-over-year growth rate of 8.6%. The business is expected to report its next earnings report on Thursday, August 1st.

According to Zacks, analysts expect that Prestige Consumer Healthcare will report full-year sales of $954.88 million for the current year, with estimates ranging from $954.00 million to $955.90 million. For the next financial year, analysts forecast that the business will post sales of $964.10 million, with estimates ranging from $963.50 million to $964.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for Prestige Consumer Healthcare.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, May 9th. The company reported $0.72 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.70 by $0.02. The company had revenue of $241.03 million for the quarter, compared to analyst estimates of $237.22 million. Prestige Consumer Healthcare had a negative net margin of 3.67% and a positive return on equity of 12.45%. The company’s revenue was down 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.62 earnings per share.

A number of equities analysts recently commented on PBH shares. Royal Bank of Canada reaffirmed a “buy” rating and set a $97.00 price target on shares of Prestige Consumer Healthcare in a research report on Friday, March 15th. TheStreet lowered shares of Prestige Consumer Healthcare from a “c” rating to a “d+” rating in a research report on Friday, May 10th. Zacks Investment Research raised shares of Prestige Consumer Healthcare from a “sell” rating to a “hold” rating and set a $31.00 price target on the stock in a research report on Tuesday, May 28th. CIBC reaffirmed a “hold” rating and set a $84.00 price target on shares of Prestige Consumer Healthcare in a research report on Monday, May 27th. Finally, ValuEngine raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “sell” rating in a research report on Monday, April 29th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $57.77.

Large investors have recently added to or reduced their stakes in the stock. Arizona State Retirement System boosted its holdings in Prestige Consumer Healthcare by 1.1% in the 4th quarter. Arizona State Retirement System now owns 37,134 shares of the company’s stock valued at $1,147,000 after purchasing an additional 400 shares in the last quarter. Xact Kapitalforvaltning AB boosted its holdings in Prestige Consumer Healthcare by 24.2% in the 4th quarter. Xact Kapitalforvaltning AB now owns 10,781 shares of the company’s stock valued at $333,000 after purchasing an additional 2,100 shares in the last quarter. Rhumbline Advisers boosted its holdings in Prestige Consumer Healthcare by 51.9% in the 4th quarter. Rhumbline Advisers now owns 164,818 shares of the company’s stock valued at $5,090,000 after purchasing an additional 56,282 shares in the last quarter. Chicago Equity Partners LLC purchased a new stake in Prestige Consumer Healthcare in the 4th quarter valued at approximately $999,000. Finally, LSV Asset Management boosted its holdings in Prestige Consumer Healthcare by 183.1% in the 4th quarter. LSV Asset Management now owns 491,784 shares of the company’s stock valued at $15,186,000 after purchasing an additional 318,043 shares in the last quarter.

NYSE:PBH opened at $31.00 on Thursday. Prestige Consumer Healthcare has a 52 week low of $26.25 and a 52 week high of $41.76. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of 10.94, a price-to-earnings-growth ratio of 1.73 and a beta of 0.89. The business’s 50-day simple moving average is $30.00. The company has a current ratio of 2.37, a quick ratio of 1.43 and a debt-to-equity ratio of 1.64.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.

Recommended Story: What is a Call Option?

Get a free copy of the Zacks research report on Prestige Consumer Healthcare (PBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.